Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

EZH2 News

News
Novel, Minimally Invasive Test Detects Higher Frequency of EZH2 Mutations in Follicular Lymphoma
11/14/2022

Gina Tomaine

Gina Tomaine
Parallel testing of both tissue and liquid biopsy samples detects a higher frequency of EZH2 mutations in patients with follicular lymphoma, with significant clinical implications, according to a recent study.
Parallel testing of both tissue and liquid biopsy samples detects a higher frequency of EZH2 mutations in patients with follicular lymphoma, with significant clinical implications, according to a recent study.
Parallel testing of both tissue...
11/14/2022
Oncology
News
Tazemetostat Reduces EZH2 Activity in Patients with Malignant Mesothelioma
07/06/2022

Derek Cowsert

Derek Cowsert
Findings from an open-label phase 2 study reveal treatment with tazemetostat reduces EZH2 activity and B-cell infiltration in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma.
Findings from an open-label phase 2 study reveal treatment with tazemetostat reduces EZH2 activity and B-cell infiltration in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma.
Findings from an open-label...
07/06/2022
Oncology
News
Valemetostat Shows Superiority in Patients With DLBCL
03/16/2022

John Otrompke

John Otrompke
Valemetostat shows efficacy for patients with DLBCL and greater EZH2-specific inhibition effects compared to current regimens.
Valemetostat shows efficacy for patients with DLBCL and greater EZH2-specific inhibition effects compared to current regimens.
Valemetostat shows efficacy for...
03/16/2022
Oncology

Advertisement

News
New Therapeutic Target Found for EZH2 Mutant Hematologic Malignancies
02/25/2022
A novel therapeutic target for mutant EZH2 expression in DLBCL and AML was discovered with feasibility to overcome resistance to current inhibitors.
A novel therapeutic target for mutant EZH2 expression in DLBCL and AML was discovered with feasibility to overcome resistance to current inhibitors.
A novel therapeutic target for...
02/25/2022
Oncology
News
Tazemetostat Shows Meaningful Response Rates in R/R FL
02/22/2022
Phase 2 trial results of tazemetostat demonstrate encouraging efficacy in patients with R/R EZH2 mutant FL.
Phase 2 trial results of tazemetostat demonstrate encouraging efficacy in patients with R/R EZH2 mutant FL.
Phase 2 trial results of...
02/22/2022
Oncology
News
EZH2 Inhibitor Valemetostat Shows Antitumor Effect in Hematologic Malignancies
02/03/2022
Primary analysis results of the EZH2 inhibitor valemetostat reveal antitumor activity against the development and progression of R/R ATL, presented at ASH 2021.
Primary analysis results of the EZH2 inhibitor valemetostat reveal antitumor activity against the development and progression of R/R ATL, presented at ASH 2021.
Primary analysis results of the...
02/03/2022
Oncology

Advertisement

News
Tazemetostat Safe, Effective for Relapsed/Refractory Malignant Mesothelioma
07/28/2020
In a phase 2 study, tazemetostat was well-tolerated and demonstrated anti-tumor activity in patients with BAP1-deficient relapsed or refractory malignant mesothelioma.
In a phase 2 study, tazemetostat was well-tolerated and demonstrated anti-tumor activity in patients with BAP1-deficient relapsed or refractory malignant mesothelioma.
In a phase 2 study, tazemetostat...
07/28/2020
Oncology
News
FDA Approves Tazemetostat for Relapsed/Refractory FL
06/18/2020
The FDA granted accelerated approval to tazemetostat for adult patients with confirmed EZH2-positive relapsed/refractory FL who have received at least 2 prior systemic therapies.
The FDA granted accelerated approval to tazemetostat for adult patients with confirmed EZH2-positive relapsed/refractory FL who have received at least 2 prior systemic therapies.
The FDA granted accelerated...
06/18/2020
Oncology
News
EZH2 Inhibitor Safe, Active in Relapsed/Refractory FL
04/20/2020
Tazemetostat was shown to be active in patients with FL in a phase 2 study, and yielded a low incidence of treatment-related AEs.
Tazemetostat was shown to be active in patients with FL in a phase 2 study, and yielded a low incidence of treatment-related AEs.
Tazemetostat was shown to be...
04/20/2020
Oncology

Advertisement

News
Tazemetostat Shows Promise in Refractory B-Cell NHL and Advanced Solid Tumors
08/17/2018
Tazemetostat therapy yields favorable safety and antitumor activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumors.
Tazemetostat therapy yields favorable safety and antitumor activity in patients with refractory B-cell non-Hodgkin lymphoma and advanced solid tumors.
Tazemetostat therapy yields...
08/17/2018
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use